TY - JOUR
T1 - Systematic versus on-demand early palliative care
T2 - A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life
AU - Maltoni, Marco
AU - Scarpi, Emanuela
AU - Dall'Agata, Monia
AU - Schiavon, Stefania
AU - Biasini, Claudia
AU - Codecà, Carla
AU - Broglia, Chiara Maria
AU - Sansoni, Elisabetta
AU - Bortolussi, Roberto
AU - Garetto, Ferdinando
AU - Fioretto, Luisa
AU - Cattaneo, Maria Teresa
AU - Giacobino, Alice
AU - Luzzani, Massimo
AU - Luchena, Giovanna
AU - Alquati, Sara
AU - Quadrini, Silvia
AU - Zagonel, Vittorina
AU - Cavanna, Luigi
AU - Ferrari, Daris
AU - Pedrazzoli, Paolo
AU - Frassineti, Giovanni Luca
AU - Galiano, Antonella
AU - Casadei Gardini, Andrea
AU - Monti, Manlio
AU - Nanni, Oriana
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Aim Early palliative care (EPC) in oncology has shown sparse evidence of a positive impact on patient outcomes, quality of care outcomes and costs. Patients and methods Data for this secondary analysis were taken from a trial of 207 outpatients with metastatic pancreatic cancer randomly assigned to receive standard cancer care plus on-demand EPC (standard arm) or standard cancer care plus systematic EPC (interventional arm). After 20 months’ follow-up, 149 (80%) had died. Outcome measures were frequency, type and timing of chemotherapy administration, use of resources, place of death and overall survival. Results Some indices of end-of-life (EoL) aggressiveness had a favourable impact from systematic EPC. Interventional arm patients showed higher use of hospice services: a significantly longer median and mean period of hospice care (P = 0.025 for both indexes) and a significantly higher median and mean number of hospice admissions (both P < 0.010). In the experimental arm, chemotherapy was performed in the last 30 days of life in a significantly inferior rate with respect to control arm: 18.7% versus 27.8% (adjusted P = 0.036). Other non-significant differences were seen in favour of experimental arm. Conclusions Systematic EPC showed a significant impact on some indicators of EoL treatment aggressiveness. These data, reinforced by multiple non-significant differences in most of the other items, suggest that quality of care is improved by this approach. This study is registered on ClinicalTrials.gov (NCT01996540).
AB - Aim Early palliative care (EPC) in oncology has shown sparse evidence of a positive impact on patient outcomes, quality of care outcomes and costs. Patients and methods Data for this secondary analysis were taken from a trial of 207 outpatients with metastatic pancreatic cancer randomly assigned to receive standard cancer care plus on-demand EPC (standard arm) or standard cancer care plus systematic EPC (interventional arm). After 20 months’ follow-up, 149 (80%) had died. Outcome measures were frequency, type and timing of chemotherapy administration, use of resources, place of death and overall survival. Results Some indices of end-of-life (EoL) aggressiveness had a favourable impact from systematic EPC. Interventional arm patients showed higher use of hospice services: a significantly longer median and mean period of hospice care (P = 0.025 for both indexes) and a significantly higher median and mean number of hospice admissions (both P < 0.010). In the experimental arm, chemotherapy was performed in the last 30 days of life in a significantly inferior rate with respect to control arm: 18.7% versus 27.8% (adjusted P = 0.036). Other non-significant differences were seen in favour of experimental arm. Conclusions Systematic EPC showed a significant impact on some indicators of EoL treatment aggressiveness. These data, reinforced by multiple non-significant differences in most of the other items, suggest that quality of care is improved by this approach. This study is registered on ClinicalTrials.gov (NCT01996540).
KW - Care aggressiveness near the end of life
KW - Early palliative care
KW - Use of health care services
UR - http://www.scopus.com/inward/record.url?scp=84993999148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84993999148&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2016.10.004
DO - 10.1016/j.ejca.2016.10.004
M3 - Article
AN - SCOPUS:84993999148
VL - 69
SP - 110
EP - 118
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
ER -